Syndax Pharmaceuticals announced 12 abstracts on Revuforj (revumenib) accepted for presentation at the EHA 2026 Congress, highlighting its efficacy across various acute leukemia subtypes and treatment stages. Data include real-world outcomes, post-transplant maintenance, and combination therapies showing deep responses and favorable tolerability. These findings reinforce Syndax's leadership in menin inhibition and support ongoing pivotal trials aimed at transforming treatment for over half of AML patients. The presentations will provide critical insights into Revuforj's potential to improve leukemia care.
Fitness Champs Holdings Limited (FCHL), penyedia pendidikan olahraga air terkemuka di Singapura, akan mengadakan Rapat Umum Pemegang Saham Luar Biasa (RUPSLB) pada 29 Juni 2026, pukul 10 pagi waktu Singapura. Pemegang saham Kelas A dan Kelas B yang t...
Verizon's stock has demonstrated resilience recently compared to other telecom carriers, maintaining its status as a solid defensive investment. Despite poor performance in the last bear market, Verizon offers a strong 6% dividend yield that appears ...
Canary Capital launched the first US spot ETF for Hedera's native token HBAR, trading under ticker HBR on Nasdaq. The ETF holds actual HBAR tokens, not derivatives, with custody by BitGo and Coinbase, and charges a 0.95% fee. This fund provides tradi...
Audiera (BEAT) led crypto gainers with a 53.10% jump to $7.32, driven by increased user adoption and new partnerships in its blockchain-based music streaming platform. Other notable gainers include Provenance Blockchain, Monero, and World Liberty Fin...
AMD posted strong Q1 results with 37.8% revenue growth and a record $2.57 billion in free cash flow, reinforcing positive investor sentiment. Despite high valuation metrics, the company is expected to benefit from new AI infrastructure products shipp...
